Endowment’s rising assets give Indy competitive edge
After a long swoon, the Lilly Endowment is packing an increasing philanthropic punch. Assets climbed to $11.8 billion in 2015, the fifth straight year they rose.
Eli Lilly and Co.
Articles
Indiana gains ground in Fortune 500 amid shuffle among elite
Indianapolis-based Simon Property Group Inc. and Warsaw’s Zimmer Biomet Holdings vaulted back among the top 500 this year, while local oil refiner Calumet Specialty Products Partners plummeted.
Merck, Pfizer double size of diabetes drug study to catch rivals
The competition heated up in the $71.5 billion global diabetes market last year after Indianapolis-based Eli Lilly’s and Boehringer Ingelheim’s Jardiance unexpectedly reduced the risk of heart attacks, strokes and deaths in a study.
CEO Lechleiter says Lilly in ‘most prolific period of new launches’
The Indianapolis-based drugmaker said Tuesday it has built a robust pipeline of drugs that “has the potential” to launch 20 new products in the 10 years between 2014 and 2023.
Judge awards ex-Lilly manager $500,000 after lawsuit
A federal judge made the award to Lilly’s former executive director of human resources, who quit for health reasons and was later dropped from the company’s extended disability plan.
Lilly sales rise, but higher costs push down profit
Lilly got a boost from a stable of new drugs but saw sales tumble for longtime stalwarts Cymbalta and Humalog. Meanwhile, R&D costs rose as the company ushered products through its late-stage pipeline.
Bristol-Myers drug tops Lilly’s Erbitux in cancer study
Bristol-Myers Squibb Co.’s blockbuster cancer drug Opdivo prolonged survival in cases of recurrent head and neck cancer, a first for patients with the harshest form of the disease who often face a bleak prognosis.
Insulin’s surging price turns diabetes staple into luxury good
The three drugmakers that dominate the world diabetes market—Eli Lilly and Co., Novo Nordisk A/S and Sanofi—are introducing improved forms of insulin, with a price tag to match.
Bipartisan trade secrets bill passed by U.S. Senate
The Senate easily passed a bill Monday allowing corporations to make a federal case of the theft of trade secrets, but a broader patent-law overhaul backed by businesses including Eli Lilly and Co. faces a rougher road.
Lilly angles for arthritis blockbuster
Within six months, Eli Lilly and Co. could know whether the Food and Drug Administration has approved its latest drug, baricitinib, a once-a-day tablet for treating rheumatoid arthritis.
Lilly wins FDA approval for plaque psoriasis drug
For Eli Lilly and Co., the approval rewards a decade-long effort to re-enter the biotech and autoimmune spaces that it helped pioneer in the 1980s but then abandoned in the 1990s.
UPDATE: Lilly shares fall after it changes goal for Alzheimer’s trial
Shares in Eli Lilly and Co. fell Tuesday on concerns surrounding the potential approval of a drug designed to treat dementia caused by Alzheimer's disease.
New life sciences research institute lands $100M donation
The Indiana Biosciences Research Institute, set up just three years ago, announced Wednesday morning that it has been awarded grants of $80 million from the Lilly Endowment and $20 million from the Eli Lilly and Co. Foundation.
For Lilly’s Cialis, glory days are over
The erectile-dysfunction drug, made famous by a slew of quirky commercials, is facing performance issues of its own.
Teva closing in on $40B buy of Allergan generics unit
Teva’s acquisition will make it the world’s largest maker of generic medicines, giving it greater negotiating power with governments and private-health insurers.
UPDATE: Lilly meets quarterly expectations but trims forecast
Strong sales of drugs for diabetes, cancer and animals helped the Indianapolis drugmaker overcome falling sales of older drugs for depression and osteoporosis, pushing up fourth-quarter sales and profit.
Lilly’s 2016 sales, profit guidance falls short of predictions
Indianapolis-based Eli Lilly and Co., which has promised to return to growth after a half-decade of falling revenue, indicated that 2016 earnings might be below analysts’ estimates.
Lilly could pay $800M-plus in pact with drug-tech firm
The companies will work on coupling therapies from Lilly with technology from Halozyme Therapeutics that helps the body disperse and spread medicine.
FDA OKs once-a-day insulin that could be blockbuster for Lilly
The FDA said Wednesday it approved Basaglar based on data showing it is safe and effective and works similarly to Lantus, the world’s top-selling insulin.
Lilly’s latest dividend increase carries on long tradition
Until impending patent expirations spurred the company to forgo a dividend increase in 2010, the company had announced dividend increases for 42 consecutive years.